Clinical trial
Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk…
NCT00033358 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00033358 |
|---|---|
| Title | Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer |
| Official title | Modulation Of Putative Surrogate Endpoint Biomarkers In Endometrial Biopsies From Women With HNPCC |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Endometrial Cancer |
| Intervention type | Drug, Other |
| Interventions | medroxyprogesterone, ethinyl estradiol, norgestrel, laboratory biomarker analysis |
| Enrollment | 52 |
| Start date | Feb 1, 2002 |
| Primary completion | Oct 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | May 3, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: